Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aya Satoki"'
Publikováno v:
Oncology. 100:188-194
Background: Bortezomib is used as first-line therapy for multiple myeloma. Observational studies based on the FDA Adverse Event Reporting System database analysis and systematic reviews indicate that the incidence of peripheral neuropathy (PN) and tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88c9d9e2cb393a16c3cab7f1811fd83a
https://doi.org/10.1159/000521448
https://doi.org/10.1159/000521448
Publikováno v:
Oncology. 100:60-64
Background: Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration. Observational studies based on systematic reviews and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e5b2b77be86cc6e77303473f03a1c97
https://doi.org/10.1159/000519687
https://doi.org/10.1159/000519687
Publikováno v:
Oncology; 2022, Vol. 100 Issue 3, p188-194, 6p
Autor:
Nakao, Shuhei, Uchida, Mayako, Satoki, Aya, Okamoto, Kenya, Uesawa, Yoshihiro, Shimizu, Tadashi
Publikováno v:
Oncology; 2022, Vol. 100 Issue 1, p60-64, 5p